^
Association details:
| Biomarker: | MTAP deletion |
|---|---|
| Cancer: | Glioblastoma |
| Drug: | TNG908 (PRMT5 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
3452 - TNG908, a brain-penetrant MTA-cooperative PRMT5 inhibitor, is efficacious in preclinical glioblastoma models
Published date:
03/15/2023
Excerpt:
In preclinical in vitro studies, the antiproliferation activity of TNG908 was 15 times more potent in MTAP-null cancer cell lines than in MTAP WT cells….TNG908 demonstrated dose-dependent antitumor activity in multiple hyper- and hypomethylated GBM subcutaneous models, including cell lines and patient-derived xenograft models....TNG908 is a potent, brain-penetrant small molecule PRMT5 inhibitor that is selective for MTAP-null tumor cells with good drug-like properties and strong antitumor activity in preclinical models of GBM.
